DNLIDenali Therapeutics Inc.

Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.

BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.

AVLAYAH revenue hit $3.6M in first full quarter post-approval.

Moby summary of Denali Therapeutics Inc.'s Q2 2026 earnings call

Denali Therapeutics (NASDAQ:DNLI) reported $3.6 million in net product revenue from AVLAYAH during the second quarter of 2026, its first full quarter of commercial availability, as the company expanded payer access and advanced two Alzheimer’s disease programs into clinical development. Chief Execu

Denali Therapeutics (DNLI) delivered earnings and revenue surprises of +5.56% and +143.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Denali Therapeutics (DNLI) is scheduled to present at the Alzheimer’s Association International Conference in London on July 12, 2026, where CEO Ryan J. Watts will be speaking. The event is drawing renewed attention to the stock. See our latest analysis for Denali Therapeutics. The upcoming AAIC presentation sits against a backdrop where Denali Therapeutics’ share price has climbed 45.30% year to date and its 1 year total shareholder return of 63.37% contrasts with weaker 3 and 5 year total...

Denali Therapeutics stock has delivered a 71.8% return over the past year, yet current valuation checks suggest the shares are trading at a premium, with both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples pointing to an overvalued picture. A 71.8% one year return sets a high bar for future expectations and can leave less room for disappointment in the share price. The recent FDA approval of Avlayah and positive analyst coverage may support higher revenue...

Lilly’s neuroscience chief discusses the large pharma’s aims in brain science, and how diagnostics and dosing are driving its next advancements in Alzheimer’s.

By Daniella Parra VERAXA Biotech said it received positive scientific advice from Germany’s Paul-Ehrlich-Institute supporting a preclinical development plan for its experimental BiTAC-TCE cancer therapy platform. The feedback provides greater regulatory clarity and reduces some early-stage development risk as the company advances its lead candidate toward clinical trials, it said. READ MORE The Cancer […] The post VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform appeared first

By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25 years of life sciences leadership experience, including serving as CFO of Verona Pharma, where he helped guide […] The post Slate Medicines Appoints Mark W. Hahn to Board of Directors appeared first on ExecEdge.

Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.